A detailed history of Jump Financial, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Jump Financial, LLC holds 186,752 shares of NTLA stock, worth $1.77 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
186,752
Holding current value
$1.77 Million
% of portfolio
0.08%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$19.72 - $27.36 $3.68 Million - $5.11 Million
186,752 New
186,752 $3.84 Million
Q1 2024

May 13, 2024

BUY
$23.82 - $32.8 $1.25 Million - $1.72 Million
52,560 New
52,560 $1.45 Million
Q3 2023

Oct 21, 2024

BUY
$31.62 - $45.78 $452,007 - $654,425
14,295 New
14,295 $452,000
Q3 2023

Nov 07, 2023

BUY
$31.62 - $45.78 $452,007 - $654,425
14,295 New
14,295 $452,000
Q4 2022

Feb 13, 2023

BUY
$33.21 - $62.69 $1.95 Million - $3.69 Million
58,840 Added 704.5%
67,192 $2.34 Million
Q3 2022

Nov 07, 2022

SELL
$53.92 - $71.7 $3.45 Million - $4.59 Million
-64,048 Reduced 88.46%
8,352 $467,000
Q2 2022

Aug 09, 2022

BUY
$38.49 - $76.21 $1.07 Million - $2.12 Million
27,846 Added 62.5%
72,400 $3.75 Million
Q1 2022

May 12, 2022

BUY
$58.27 - $118.99 $1.97 Million - $4.03 Million
33,831 Added 315.5%
44,554 $3.24 Million
Q4 2021

Feb 10, 2022

SELL
$100.76 - $138.36 $108,518 - $149,013
-1,077 Reduced 9.13%
10,723 $1.27 Million
Q3 2021

Nov 12, 2021

BUY
$132.37 - $176.78 $1.56 Million - $2.09 Million
11,800 New
11,800 $1.58 Million
Q1 2021

May 17, 2021

SELL
$46.59 - $83.68 $251,586 - $451,872
-5,400 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$18.83 - $63.53 $101,681 - $343,062
5,400 New
5,400 $294,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $722M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Jump Financial, LLC Portfolio

Follow Jump Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jump Financial, LLC with notifications on news.